Dr. Masaaki Ban, Director of Roppongi Ladies Clinic Ikebukuro, Leads Publication of Research Paper in Journal of the Japan Society for Reproductive Medicine
Real-World Cases Examine the Possibility of Reclassification in PGT-A Results; Findings Expected to Contribute to Individualized, Patient-Centered Fertility Treatment
IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that Dr. Masaaki Ban, Director of Roppongi Ladies Clinic Ikebukuro, a fertility specialty clinic under SBC Medical's management support, has published a collaborative research paper as lead author in the Journal of the Japan Society for Reproductive Medicine (Vol. 43, No. 1, 2026), an academic journal of the Japan Society for Reproductive Medicine. The paper is titled "Uncertainty in Aneuploidy Assessment in Preimplantation Genetic Testing: Two Cases of Reclassification as Mosaic Following PGT-A Reanalysis, Resulting in Healthy Births."
The Journal of the Japan Society for Reproductive Medicine is an academic publication that brings together researchers and clinical specialists in fertility treatment and reproductive science. The paper presents insights regarding the interpretation of test results in PGT-A (Preimplantation Genetic Testing for Aneuploidy)*1, a methodology widely used in fertility treatment to improve implantation rates and reduce the risk of miscarriage, and highlights the importance of individualized, informed decision-making support for each patient.
Among embryos assessed as aneuploid through PGT-A, a subtype known as "mosaic embryos," in which normal and abnormal cells coexist, may be present, and the evaluation and clinical management of such embryos continue to be actively discussed in the field. The paper reports two cases in which embryos initially assessed as aneuploid were reclassified as mosaic embryos upon reanalysis, ultimately resulting in the birth of healthy infants. These findings are expected to deepen understanding of the importance of result interpretation and reassessment in PGT-A, and to inform the development of flexible, individualized decision-making support and more thorough clinical frameworks suited to each patient's unique circumstances.
As technological innovation continues to advance in the rapidly evolving field of reproductive medicine, the importance of knowledge sharing and academic collaboration — beyond the clinical setting alone — has grown considerably. Meeting the increasingly diverse needs of patients requires not only the adoption of cutting-edge techniques, but also broad perspectives and flexible thinking. SBC Medical remains committed to promoting advanced initiatives through academic activities and research collaborations, and to building a more reassuring medical environment for patients and advancing the field of reproductive medicine.
*1 PGT-A (Preimplantation Genetic Testing for Aneuploidy): A test used to examine the chromosomal composition of embryos obtained through in vitro fertilization (IVF), employed for the purpose of improving implantation rates and reducing the risk of miscarriage.
Publication Details
Journal: Journal of the Japan Society for Reproductive Medicine
Volume/Issue: Vol. 43, No. 1, pp. 65–70, 2026
Paper Title: "Uncertainty in Aneuploidy Assessment in Preimplantation Genetic Testing: Two Cases of Reclassification as Mosaic Following PGT-A Reanalysis, Resulting in Healthy Births"
Authors: Masaaki Ban, Tatsuhito Inohana, Kazuko Takahashi, Maki Kusumi, Osamu Tsutsumi
About Dr. Masaaki Ban
Dr. Ban graduated from the Faculty of Medicine at the University of Miyazaki and subsequently deepened his expertise in obstetrics and gynecology at the National Center for Global Health and Medicine and Keio University Hospital, before further advancing his experience in advanced reproductive medicine at a specialized fertility clinic. He joined Roppongi Ladies Clinic in 2023. Currently serving as Director of the Roppongi Ladies Clinic Ikebukuro, he is also engaged in research on PGT-A at the Graduate School of International University of Health and Welfare, contributing to the advancement of reproductive medicine from both clinical and academic perspectives. For more information on Dr. Ban’s professional profile, please visit [here].
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp